Table 1 Baseline characteristics (n = 39).
Age (median, range) | 62 (34–83) N (%) |
|---|---|
Sex | |
Male | 28 (71.8%) |
Female | 11 (28.2%) |
Histological subtype | |
Adenocarcinoma | 18 (46.1%) |
Squamous cell carcinoma | 19 (48.7%) |
Adenosquamous carcinoma | 2(5.1%) |
ECOG PS score at the time of pembrolizumab initiation | |
0 | 17 (43.6%) |
1 | 19 (48.7%) |
2 | 3 (7.7%) |
Stage at the time of pembrolizumab initiation | |
IIIB | 3(7.7%) |
IIIC | 8(20.5%) |
IVA | 18 (46.2%) |
IVB | 10(25.6%) |
Smoking history | |
never | 12 (30.7%) |
yes | 27 (69.2%) |
Pembrolizumab initiation (line of therapy) | |
1 | 26 (66.7%) |
2 | 7 (17.9%) |
≥3 | 6 (15.4%) |
PD-L1 status | |
positive | 16 (41.0%) |
Negative/Unknown | 23 (59.0%) |
EGFR Genetic testing (non-squamous cell carcinoma, n = 4) | |
EGFR exon 19 deletion | 1 (25%) |
EGFR exon21 L858R | 2 (50%) |
EGFR exon 21 L861Q | 1 (25%) |
